---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-200433"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2022-07-25T23:59:59+00:00"
generated_at: "2026-06-24T09:18:01.850892+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Ginkgo to acquire Zymergen for ~$300M all-stock; Zymergen holders get 0.9179 DNA shares

## Summary
- Deal valued at ~$300M market cap; fixed exchange ratio of 0.9179 Ginkgo shares per Zymergen share.
- Zymergen stockholders will own 5.25% of pro forma combined company after transaction close.
- Voting agreements from holders of ~40% of Zymergen shares to vote in favor of the merger.
- Integration expected to accelerate Ginkgo's platform; Zymergen to evaluate strategic alternatives for Advanced Materials and Drug Discovery.
- Transaction subject to regulatory approvals, Zymergen stockholder vote, and other conditions; expected close by Jan 24, 2023 with extension options.

## SEC filing metadata
- accession: 0001193125-22-200433
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2022-07-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000119312522200433/0001193125-22-200433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000119312522200433/d368627d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-200433
- JSON: https://secwatch.observer/filing/0001193125-22-200433.json
- Plain text: https://secwatch.observer/filing/0001193125-22-200433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.